PREPrenetics Global Limited
$22.08+54% 1Y
$22.08
$11.7952 weeks$26.30
Is the business good?
How good a business is PRE?
Prenetics Global Limited earns −35% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−35%
Return on invested capital · cost of capital 9.0% · 44 points below what the capital costs: growth destroys value
- Operating margin
- −157%
Operating margin · Diagnostics & Research median 3.6% · fiscal year to FY2024
- Share count, year on year
- +11%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 36%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −1.5% |
| FY2021 | −452% |
| FY2022 | −502% |
| FY2023 | −239% |
| FY2024 | −157% |
Details›
- Gross marginfiscal year to FY2024
- 50%
- Operating marginfiscal year to FY2024
- −157%
- Net marginfiscal year to FY2024
- −151%
- Free cash flow margin
- −98%
- R&D as % of revenue
- 36%
- Revenue, trailing twelve months
- $31M
- Free cash flow, trailing twelve months
- −$30M
- Net income, trailing twelve months
- −$46M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −35%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Diagnostics & Research
Ranks #10 of 21 by RyuScore